Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALC NASDAQ:LVTX NASDAQ:RENB NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$2.70-1.1%$2.59$1.42▼$5.97$37.72M1.3232,449 shs9,187 shsLVTXLAVA Therapeutics$1.57+1.3%$1.45$0.85▼$2.09$41.30M0.5204,468 shs161,708 shsRENBRenovaro$0.24-6.1%$0.28$0.22▼$2.10$40.96M0.54840,996 shs720,559 shsTRAWTraws Pharma$1.40-1.4%$1.51$0.97▼$19.44$9.89M1.52146,839 shs45,825 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica0.00%-2.88%-8.16%+64.63%-35.25%LVTXLAVA Therapeutics0.00%+2.61%+10.56%+21.71%-10.29%RENBRenovaro0.00%-0.42%-7.93%-17.90%-60.24%TRAWTraws Pharma0.00%-0.71%-4.11%-1.41%+139,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALCCalciMedica3.4048 of 5 stars3.55.00.00.03.03.30.0LVTXLAVA Therapeutics2.346 of 5 stars3.05.00.00.03.80.00.0RENBRenovaro1.129 of 5 stars0.05.00.00.01.51.70.6TRAWTraws Pharma1.7239 of 5 stars0.05.00.00.02.70.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 3.00Buy$16.00492.59% UpsideLVTXLAVA Therapeutics 2.00Hold$2.6971.02% UpsideRENBRenovaro 0.00N/AN/AN/ATRAWTraws Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRAW, LVTX, RENB, and CALC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$1.50 ➝ $1.248/5/2025LVTXLAVA TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$3.00 ➝ $1.50(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A$1.07 per shareN/ALVTXLAVA Therapeutics$11.98M3.45N/AN/A$1.06 per share1.48RENBRenovaroN/AN/AN/AN/A$0.89 per shareN/ATRAWTraws Pharma$230K42.97N/AN/A($8.66) per share-0.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$13.70M-$1.60N/AN/AN/AN/A-206.51%-103.81%11/12/2025 (Estimated)LVTXLAVA Therapeutics-$25.11M-$1.05N/AN/AN/AN/A-106.29%-38.24%N/ARENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%9/29/2025 (Estimated)TRAWTraws Pharma-$166.52M$88.830.02N/AN/A3,028.25%-1,812.48%512.72%11/12/2025 (Estimated)Latest TRAW, LVTX, RENB, and CALC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TRAWTraws Pharma-$8.75-$0.11+$8.64-$0.11$0.06 million$2.73 million8/13/2025Q2 2025LVTXLAVA Therapeutics-$0.28-$0.32-$0.04-$0.32N/AN/A8/12/2025Q2 2025CALCCalciMedica-$0.40-$0.40N/A-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedica1.395.455.45LVTXLAVA TherapeuticsN/A10.7810.78RENBRenovaroN/A0.130.13TRAWTraws PharmaN/A2.092.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/ALVTXLAVA TherapeuticsN/ARENBRenovaro71.41%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%LVTXLAVA Therapeutics9.50%RENBRenovaro0.50%TRAWTraws Pharma13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3013.97 million8.17 millionNo DataLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableRENBRenovaro20172.12 million171.26 millionOptionableTRAWTraws Pharma177.06 million6.10 millionOptionableTRAW, LVTX, RENB, and CALC HeadlinesRecent News About These CompaniesTraws Pharma Earnings Call: Optimism Amid ChallengesAugust 31 at 9:30 PM | tipranks.comTraws Pharma receives approval to proceed with Phase 2 COVID studiesAugust 18, 2025 | msn.comTraws Pharma, Inc.: Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025August 18, 2025 | finanznachrichten.deTraws Pharma Gains Approval for Phase 2 COVID-19 TrialsAugust 18, 2025 | msn.comTraws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025August 18, 2025 | globenewswire.comTraws Pharma Reports Q2 Results, Advances COVID-19 and Influenza Antiviral ProgramsAugust 16, 2025 | msn.comTraws Pharma Advances Antiviral Programs Amid Revenue GrowthAugust 16, 2025 | theglobeandmail.comTraws Pharma, Inc. (NASDAQ:TRAW) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | insidermonkey.comTraws Pharma, Inc.: Traws Pharma Reports Second Quarter 2025 Results and Business HighlightsAugust 14, 2025 | finanznachrichten.deTraws Pharma Stock Short Interest Report | NASDAQ:TRAW - BenzingaAugust 14, 2025 | benzinga.comTraws Pharma Posts Q2 Revenue JumpAugust 14, 2025 | aol.comATraws Pharma reports Q2 EPS (11c) vs. ($20.52) last yearAugust 14, 2025 | msn.comTraws Pharma Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comTraws Pharma Reports Second Quarter 2025 Results and Business HighlightsAugust 14, 2025 | finance.yahoo.comTraws Pharma, Inc. (TRAW) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comTraws Pharma Reports Second Quarter 2025 Results and Business HighlightsAugust 14, 2025 | globenewswire.comTraws Pharma to Announce Q2 Results and Business Update on August 14August 10, 2025 | msn.comTraws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025August 8, 2025 | globenewswire.comTRAW - Traws Pharma Inc Sustainability - MorningstarJuly 16, 2025 | morningstar.comMCooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws PharmaJuly 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025TRAW, LVTX, RENB, and CALC Company DescriptionsCalciMedica NASDAQ:CALC$2.70 -0.03 (-1.10%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.73 +0.03 (+1.11%) As of 08/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.LAVA Therapeutics NASDAQ:LVTX$1.57 +0.02 (+1.29%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Renovaro NASDAQ:RENB$0.24 -0.02 (-6.11%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.24 +0.00 (+1.68%) As of 08/29/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Traws Pharma NASDAQ:TRAW$1.40 -0.02 (-1.41%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.38 -0.01 (-1.07%) As of 08/29/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
